Expert consensus on treatment for stage III non‐small cell lung cancer
Yi‐Long Wu, Shun Lü, Qinghua Zhou, Li Zhang, Ying Cheng, Jie Wang, Buhai Wang, Chengping Hu, Lizhu Lin, Wen‐Zhao Zhong, Yong Song, Nong Yang, Xiaorong Dong, Jian Zhao, Haihong Yang, Hui Guo, Xiaolong Yan, Hongxu Liu, Rui Ma, Jie Lin, Si‐Yang Liu, Chun Chen, Lifeng Wang, Chengzhi Zhou, Ming Zhou, Fang Wu, Xue‐Ning Yang, Yingying Du, Yu Yao, Yang Shao, Shaodong Hong, Jiuwei Cui, Xueping Quan, Rongrong Chen, Jiayan Wu, Jia‐Tao Zhang, Jianya Zhou, Binchao Wang, Chao Cheng, Huijuan Wang, Jingjing Liu, Lin Wu, Yan Huang, Yukun Kuang, Yongchang Zhang, Jia Hu, Jin‐Ji Yang, Weineng Feng, Wenmei Su, Yun Fan, Fan Yang, Ming Chen, Kejing Tang, Yi Pan, Peng Shen, Anwen Liu, Haibo Zhang, Wenhua Liang, Qing Zhou, Zhiyong Ma, Xiuyu Cai, Hui Liu, Longfei Chen, Shaokun Chuai, Jianzhen Shan, Yanfang Zheng, Changxuan You, Xiaoxia Zhu, Li Li, Tongmei Zhang, Hai‐Yan Tu, Wurong Lin, Xu‐Chao Zhang, Penghui Zhou, Zunfu Ke, Huiying Liang
Abstract
Abstract Stage III non‐small cell lung cancer (NSCLC) encompasses a group of diseases with high heterogeneity. Such patients should actively receive comprehensive treatments. It is imperative for all stage III NSCLC patients to receive consultation with a multiple disciplinary team, which allows the development of a proposal for clinical diagnosis and treatment. In this consensus, stage III NSCLC is divided into two types (operable and inoperable) according to different clinical conditions. Resectable NSCLC is further subdivided into two conditions (with or without driver genes). For each clinical scenario, this consensus emphasizes that the foundation of any medical decisions regarding the optimal diagnostic or therapy procedure is scientific evidence from clinical research. Finally, based on the level of evidence and strength of recommendations, this consensus provides recommendations for the management of stage III NSCLC from six perspectives. The objective of this consensus is to help clinicians choose the best treatment and promote the standardization of stage III NSCLC diagnosis and treatment in China.